MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards
Palace fans can now download the MyGuava App and order a custom- designed Crystal Palace Card.Cards will provide users with cashback on all purchases, with up to 7% available for limited edition cards at any sporting goods store.900 ‘Palace Gold’ cards will also be made available, with each card providing the user with enhanced cashback and exclusive club benefits.
MyGuava in association with Crystal Palace Football Club is thrilled to launch exclusive Crystal Palace Fan Cards with rewards and a variety of perks as well as a unique opportunity for fans to celebrate their connection to the club while enjoying MyGuava’s seamless payment solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101068560/en/
MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards (Photo: Business Wire)
Palace fans can now download the MyGuava App and order a Crystal Palace Card, choosing from three custom-designed cards: ‘Palace Gold’, ‘Palace Sash’ and ‘Selhurst 100’.
Each card comes packed with perks, including entry into exclusive prize draws, cashback on all purchases, giving Palace fans an opportunity to take advantage of the 7% cashback offer ahead of the festive period. Additionally, the cards come with Visa Platinum status for added financial flexibility.
Furthermore, for the most dedicated Eagles supporters, 900 limited-edition ‘Palace Gold’ cards will be available on a first come first served basis, offering enhanced cashback rates and special access to exclusive club benefits.
Rewards System
The MyGuava and Crystal Palace card will also be introducing a multi-stage reward system, providing cardholders with the exciting chance to earn Crystal Palace merchandise and experience based on spending. Supporters can win Crystal Palace branded bottles, t-shirts, hoodies as well as stadium tours and even personalised messages from the team for completing transaction milestones.
The MyGuava App, which is the flagship product of Guavapay, is designed to meet the broad financial needs of users. Users can open accounts in 20 currencies, make seamless local and global transfers, and use both virtual and physical debit cards. The App also has significant global reach, with access to 140 countries in more than 90 currencies and there are additional benefits with discounted gift cards from top brands and tools for enhancing user experience, such as digital skins, spending management tools and vaults.
To learn more about the Crystal Palace Card and Reward scheme, please visit the link below:
https://myguava.com/personal/landings/crystalpalace-cobrand-card
About Guavapay
Guavapay is a global fintech company with headquarters in London. The company has built a global financial ecosystem to empower individuals and businesses and give them more control over their financial lives. The All Things Payments App, MyGuava and the B2B platform, MyGuava Business simplify financial services, making them more accessible and affordable for people who have historically been overlooked.
The MyGuava Application is owned and operated by Guavapay Limited, a company registered in England with company number 10601900 and its registered address at Salisbury House, 29 Finsbury Circus, London, EC2M 5QQ, United Kingdom. Guavapay Limited is registered with the Financial Conduct Authority in the United Kingdom as a Small Electronic Money Institution with reference number 900888. Guavapay Limited’s ICO registration number is ZA274504.
For more information, please visit www.guavapay.com or contact:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101068560/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom